Edition:
United States

Qiagen NV (QIA.DE)

QIA.DE on Xetra

33.06EUR
11:14am EDT
Change (% chg)

€0.01 (+0.03%)
Prev Close
€33.05
Open
€33.00
Day's High
€33.32
Day's Low
€32.94
Volume
232,217
Avg. Vol
504,332
52-wk High
€33.91
52-wk Low
€25.22

Summary

Name Age Since Current Position

Manfred Karobath

77 2016 Independent Chairman of the Supervisory Board

Peer Schatz

52 2004 Chief Executive Officer, Managing Director, Member of the Executive Committee

Roland Sackers

49 2016 Chief Financial Officer, Member of the Executive Committee

Annette Koch

2018 Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee

Manuel Mendez

Senior Vice President Global Commercial Operations, Member of the Executive Committee

Thierry Bernard

Senior Vice President Molecular Diagnostics Business Area, Member of the Executive Committee

Mark Gladwell

43 2017 Senior Vice President Global Operations, Member of the Executive Committee

Thomas Schweins

2017 Senior Vice President, Life Science Business Area, Member of the Executive Committee

Jonathan Sheldon

2018 Senior Vice President, Member of the Executive Committee

John Gilardi

Vice President Corporate Communications

Stephane Bancel

45 2013 Independent Member of the Supervisory Board

Hakan Bjorklund

61 2017 Independent Member of the Supervisory Board

Metin Colpan

63 2004 Independent Member of the Supervisory Board

Ross Levine

46 2016 Independent Member of the Supervisory Board

Elaine Mardis

55 2014 Independent Member of the Supervisory Board

Lawrence Rosen

61 2013 Independent Member of the Supervisory Board

Elizabeth Tallett

68 2011 Independent Member of the Supervisory Board

Biographies

Name Description

Manfred Karobath

Prof. Dr. Manfred Karobath has served as Independent Chairman of the Supervisory Board of Qiagen N.V. since 2016. Prior to this, he was Independent Member of the Supervisory Board at the Company between 2000 and 2016. He has been a member of the Supervisory Board since 2000 and joined the Compensation Committee in 2005. He has served as a member of the Science and Technology Committee since 2014 and he is also Chairman of the Selection and Appointment Committee. Prof. Dr. Karobath studied medicine, and from 1967 to 1980 he worked first in the Dept. of Biochemistry of the University of Vienna and, after a stage as postdoctoral fellow, he joined the Dept. of Psychiatry where he became Professor of Biological Psychiatry. In 1980, he joined Sandoz Pharma in Basel, first in drug discovery, and later becoming Senior Vice President and head of R&D. In 1992, Prof. Dr. Karobath joined Rhone Poulenc Rorer (RPR) as President of R&D and Executive Vice President, and later, he became a member of the boards of directors of RPR, Pasteur Merieux Connought, Centeon and Rhone Poulenc Pharma. He has received several scientific awards and has published 92 scientific papers.

Peer Schatz

Mr. Peer M. Schatz has served as Chief Executive Officer, Managing Director, Member of the Executive Committee of Qiagen N.V. since January 1, 2004. He joined QIAGEN in 1993, when the Company had just 30 employees and revenues of approximately $2 million, and has been Chief Executive Officer since January 1, 2004. He was Chief Financial Officer between 1993 and 2003 and became a member of the Managing Board in 1998. Mr. Schatz was previously a partner in a private management buyout group in Switzerland, worked in finance and systems positions in Sandoz, Ltd. and Computerland AG, and participated in the founding of start-up companies in the computer and software trading industry in Europe and the United States. Mr. Schatz graduated from Universitaet St. Gallen, Switzerland, with a Master's degree in Finance in 1989 and obtained an M.B.A. in Finance from the University of Chicago Graduate School of Business in 1991. Mr. Schatz served as a member of the German Corporate Governance Commission from 2002 to 2012. He is a board member of AdvaMedDx, an advocacy dedicated to issues facing the in vitro diagnostics industry in the United States and Europe, and ALDA (the Analytical, Life Science and Diagnostics Association), a trade association of developers and suppliers in these fields.

Roland Sackers

Mr. Roland Sackers has served as Chief Financial Officer, Member of the Executive Committee of Qiagen N.V. since 2016. He joined the Company in 1999 as Vice President Finance and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. Mr. Sackers earned his Master Degree Business Administration (Diplom-Kaufmann) from Westfaelische Wilhelms-Universitaet Muenster. He is a former member of the Supervisory Board and Audit Committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is a board member of the industry association BIO Deutschland. He is also a non-executive director and chair of the audit committee of Immunodiagnostic Systems Holding PLC (IDS), a producer of immunological tests for research and diagnostic applications publicly listed in the United Kingdom.

Annette Koch

Dr. Annette Koch has served as Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee of Qiagen N.V. since 2018. Joined QIAGEN in 2018 as Senior Vice President and Chief Human Resources Officer, overseeing all aspects of QIAGEN’s global Human Resources function. She came to QIAGEN from Eppendorf AG, where she had been Vice President Human Resources since 2013, supporting about 3,200 employees in 26 countries. Previously, she held roles of increasing responsibility from 2003 to 2013 with Boehringer Ingelheim. Dr. Koch started her career at The Boston Consulting Group in Düsseldorf, working on projects in the pharmaceutical and chemical industries. She earned a Ph.D. in Organic Chemistry from the University of Hannover, and during her graduate studies also worked in the University of Southern California laboratory of Prof. George Andrew Olah, who had won the Nobel Prize in Chemistry in 1994.

Manuel Mendez

Mr. Manuel O. Mendez serves as Senior Vice President Global Commercial Operations, Member of the Executive Committee of Qiagen N.V. He leads QIAGEN’s commercial organizations worldwide. He joined QIAGEN in 2014 with 25 years of experience in diagnostics and life sciences, most recently as Executive Vice President Americas for bioMerieux since 2010. Previously he served in sales, marketing and general management roles with Abbott Laboratories, Thermo Fisher Scientific and OraSure Technologies – with leadership experience in the United States, Latin America, Europe and Asian markets. He serves on the advisory board of 908 devices, a maker of point-of-need chemical analyzers, and the board of VillageCare, a New York nonprofit serving persons with chronic care needs. He received a BS in Biomedical Engineering from Boston University and an MBA from Northwestern University Kellogg School of Management.

Thierry Bernard

Mr. Thierry Bernard serves as Senior Vice President Molecular Diagnostics Business Area, Member of the Executive Committee of Qiagen N.V. He leads QIAGEN’s growing presence in diagnostic solutions for healthcare. Mr. Bernard joined the QIAGEN team in February 2015 from bioMerieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMérieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Boards of Directors of three privately held U.S. companies, AdvanDx, HepatoChem and more recently, Daktari Diagnostics, where he also served as CEO. He has earned degrees from Institut de Sciences Politiques de Paris or Sciences Po, Harvard Business School, London School of Economics and the College of Europe and is a member of French Foreign Trade Advisors.

Mark Gladwell

Mr. Mark Gladwell has served as Senior Vice President Global Operations, Member of the Executive Committee of Qiagen N.V. since 2017. Joined QIAGEN in 2017 as Senior Vice President Global Operations. He leads Manufacturing, Supply Chain, Customer Care, Quality Assurance & Control, and Regulatory Affairs at QIAGEN. Mr. Gladwell has more than two decades of experience in manufacturing high-volume, high technology in vitro diagnostics and medical devices. He joined QIAGEN from Alere Inc., where he served in positions of increasing responsibility for 12 years, most recently as Senior Vice President, Global Operations. Previously, he was with Johnson & Johnson, Agfa HealthCare, Sterling Medical Imaging and DuPont. Mark received a bachelor’s degree with honors from the University of Salford in the United Kingdom and is a graduate of the General Management Program from Harvard Business School.

Thomas Schweins

Dr. Thomas Schweins has served as Senior Vice President, Life Science Business Area, Member of the Executive Committee of Qiagen N.V. since 2017. He was Senior Vice President - Human Resources, Strategy & Marketing Services of the Company between 2012 and 2017. He leads QIAGEN’s initiatives to maximize human capital as well as the corporate strategy and marketing services teams. He joined QIAGEN in 2004 as Vice President Corporate Strategy and became Vice President Marketing & Strategy in 2005. In 2012 Dr. Schweins was named Senior Vice President Human Resources, Strategy & Marketing Services. He joined QIAGEN from The Boston Consulting Group, where he was a core team member of the Pharma/Health Care Area as well as the Corporate Development Practice Area. Before this, Dr. Schweins worked as Technology Manager and later as Assistant to the Management Board with Hoechst/Aventis. Dr. Schweins has a degree in Biochemistry from the University of Hanover. He obtained his Ph.D. at the Max-Planck-Gesellschaft / Max Planck Soceity and received a M.S. from the University of Southern California in Los Angeles, where he studied Business Administration and Chemistry.

Jonathan Sheldon

Dr. Jonathan Sheldon has served as Senior Vice President, Member of the Executive Committee of Qiagen N.V. since 2018. Joined QIAGEN in 2018 as Senior Vice President, Bioinformatics Business Area. He leads QIAGEN's growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights. Dr. Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle's Healthcare business globally in the Health Sciences Global Business Unit and served on the executive committee. Previously, he established the bioinformatics group and served as Head of Bioinformatics at Roche (UK) Pharmaceuticals, as well as providing leadership in software firms serving the life science and healthcare sectors. He serves on the Board of Directors of the Drug Information Association (DIA). He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.

John Gilardi

Stephane Bancel

Mr. Stephane Bancel has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2013. He joined the Company's Supervisory Board as well as the Compensation Committee in 2013 and joined the Audit Committee and Science and Technology Committee in 2014. He is President and Founding Chief Executive Officer of Moderna Therapeutics, Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, which is advancing multiple drug development programs involving messenger RNA therapeutics. Before joining Moderna, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. Prior to bioMerieux, he was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis, Indiana, after having started at Lilly in Great Britain. Before joining Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMerieux while based in Tokyo, Japan. He holds a Master of Engineering degree from Ecole Centrale Paris (ECP), a Master of Science in Chemical Engineering from the University of Minnesota and an M.B.A. from Harvard Business School. He is Member of the Audit Committee, Member of the Compensation Committee, Member of the Selection and Appointment Committee, and Member of the Science and Technology Committee of the Company.

Hakan Bjorklund

Dr. Hakan Bjorklund has served as Independent Member of the Supervisory Board of Qiagen N.V. since March 2017. He is Member of the Compensation Committee, Member of the Selection and Appointment Committee of the Company. Dr. Bjorklund brings an international background in the life science industry to QIAGEN, in particular through his current role as Operating Executive at Avista Capital Partners, as well as through previous roles as CEO of the global pharmaceutical company Nycomed, Regional Director at Astra (now AstraZeneca) and President of Astra Draco. Under Mr. Bjorklund’s leadership, Nycomed grew from a predominantly Scandinavian business into a global pharmaceutical company. In addition to QIAGEN, he currently serves as Chairman of the Board of Directors at Acino International AG, Swedish Orphan Biovitrum AB (Sobi) and Trimb Healthcare AB. Dr. Bjorklund earlier served as Chairman of the Board of Directors of Lundbeck A/S, and was also a Member of the Board of Directors of several international life science companies, including Alere, Atos, Coloplast and Danisco. He has a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.

Metin Colpan

Dr. Metin Colpan has served as Independent Member of the Supervisory Board of Qiagen N.V. since January 1, 2004. He is a co-founder of QIAGEN and was the Company's Chief Executive Officer and a Managing Director from 1985 through 2003. Dr. Colpan has been a member of the Supervisory Board since 2004 and has served as Chairman of the Science and Technology Committee since 2014. He has been a member of the Selection and Appointment Committee since 2015. Dr. Colpan obtained his Ph.D. and M.S. in Organic Chemistry and Chemical Engineering from the Darmstadt Institute of Technology in 1983. Prior to founding QIAGEN, Dr. Colpan was an Assistant Investigator at the Institute for Biophysics at the University of Düsseldorf. Dr. Colpan has had wide experience in separation techniques and in the separation and purification of nucleic acids in particular, and has filed many patents in the field. Dr. Colpan also serves as a Supervisory Board member of Qalovis Farmer Automatic Energy GmbH, Laer, Germany. Dr. Colpan previously served as a Supervisory Board member of Ingenium Pharmaceuticals AG, GenPat77 Pharmacogenetics AG, GPC Biotech AG and Morphosys AG, each in Munich, Germany. He received a Master of Science in Chemical Engineering from Technische Universitaet Darmstadt in 1983, and a Doctorate in Philosophy degree in Organic Chemistry from Technische Universitaet Darmstadt in 1983.

Ross Levine

Dr. Ross L. Levine has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2016. He is a physician-scientist focused on researching and treating blood and bone marrow cancers as the Laurence Joseph Dineen Chair in Leukemia Research, the Director of the Center for Hematologic Malignancies, and an Attending Physician at Memorial Sloan Kettering Cancer Center, as well as Professor of Medicine at Weill Cornell Medical College. He leads a research lab investigating genetics and targeted therapies in myeloid malignancies and is interested in application of next-generation sequencing technology in the practice of medicine in hematologic cancers. He trained in internal medicine at Massachusetts General Hospital and in hematology-oncology at the Dana-Farber Cancer Institute, earning board certification in these specialties. He received his M.D. from the Johns Hopkins University School of Medicine and his A.B. degree from Harvard College. He is Member of Science and Technology Committee of the Company.

Elaine Mardis

Dr. Elaine R. Mardis has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2014. She joined the Company’s Supervisory Board and its Science and Technology Committee in 2014. Since 2014 she has served on the Scientific Advisory Board of Ingenuity Systems, Inc. Dr. Mardis holds over two decades experience in DNA preparation and sequencing-based research. She is the Robert E. and Louise F. Dunn Distinguished Professor of Medicine at Washington University and also serves as Co-Director of its McDonnell Genome Institute where she has worked since 1993. Prof. Dr. Mardis serves on several study sections of the U.S. National Institutes of Health, is an editorial board member of Molecular Cancer Research, Annals of Oncology, and Disease Models and Mechanisms and acts as a reviewer for Nature and The New England Journal of Medicine. Prof. Dr. Mardis also serves on the scientific advisory boards of QIAGEN Silicon Valley (formerly Ingenuity) and Regeneron Genomics Center. Between 2008 and 2009 she served on the board of directors of Applied Biosytems, Inc. Prof. Dr. Mardis is also Professor in the Department of Genetics, with an adjunct appointment in the Department of Molecular Microbiology at Washington University. Prior to joining the Washington

Lawrence Rosen

Mr. Lawrence A. Rosen has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2013. He joined the Company's Supervisory Board as well as the Audit Committee in 2013 and has served as the committee's chairman since 2014. Mr. Rosen is a member of the Board of Management and Chief Financial Officer of Deutsche Post DHL. Holding this position since 2009, Mr. Rosen is in charge of controlling, corporate accounting and reporting, investor relations, corporate finance, corporate internal audit and security, taxes, as well as the group’s global business services. Prior to joining Deutsche Post DHL, Mr. Rosen served as Chief Financial Officer of Fresenius Medical Care AG & Co. KGaA in Germany from 2003 to 2009. Prior to that, he was Senior Vice President and Treasurer for Aventis SA in Strasbourg, France. Between 1984 and 2000, Mr. Rosen held different positions at the Aventis predecessor companies Hoechst AG and American Hoechst/Hoechst Celanese Inc. Mr. Rosen holds a Bachelor in Business Administration from the State University of New York and an M.B.A. from the University of Michigan.

Elizabeth Tallett

Ms. Elizabeth E. Tallett has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2011. She joined the Company's Supervisory Board as well as the Audit Committee and Compensation Committee in 2011. She is Chairwoman of the Compensation Committee, Member of the Audit Committee and Member of the Selection and Appointment Committee. Ms. Tallett was a Principal of Hunter Partners, LLC, a management company for early to mid-stage pharmaceutical, biotechnology and medical device companies, from 2002 until February 2015. Ms. Tallett will continue to consult with early stage health care companies. Her senior management experience includes President and CEO of Transcell Technologies Inc., President of Centocor Pharmaceuticals, member of the Parke-Davis Executive Committee, and Director of Worldwide Strategic Planning for Warner-Lambert Company. Ms. Tallett graduated from The University of Nottingham, England with dual Bachelor's degrees with honors in mathematics and economics. She is a member of the board of directors of Principal Financial Group, Inc. (where she is currently the Lead Director), Anthem, Inc. and Meredith Corp. She is a former director of Varian, Inc., Immunicon, Inc., Varian Semiconductor Equipment Associates, Inc., Coventry Health Care, Inc. and IntegraMed America, Inc. Ms. Tallett was a founding board member of the Biotechnology Council of New Jersey and is a Trustee of Solebury School in Pennsylvania.